[BioS] CrossPoint Signs MOU with Samyang Biopharm to Develop Anticancer siRNA
Predicted impact: Low
Non-binding MOU for early-stage anticancer siRNA development; no financial terms or revenue size disclosed.
Samyang Biopharm삼양바이오팜
0120G0 · KOSPI · ₩0120G0 · 삼양바이오팜
₩40,900▼ ₩650 (1.56%)End-of-day · Oct 29, 2026 · End-of-day prices.
Samyang Biopharmaceuticals and CrossPoint Co-Develop Next-Generation Targeted Gene Therapy
Predicted impact: Low
Co-development MOU with CrossPoint already reported within the last 14 days.
[BioS] CrossPoint Signs MOU with Samyang Biopharm to Develop Anticancer siRNA
Predicted impact: Low
Non-binding MOU for early-stage anticancer siRNA development; no financial terms or revenue size disclosed.
Also known as: Samyang Biopharm / 삼양바이오팜 / 0120G0 / KRX:0120G0
Source: KRX statistical information